Armistice Capital Master Fund Ltd., Director, 10% Owner at Avalo Therapeutics, Inc. (AVTX), bought 140,000 shares at $0.80 ($112K) on 2022-02-24, disclosed to the SEC on 2022-02-28.
Open-market purchase of $112k AVTX by Director, 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.80 | 100,000 | $80K | 71.7% |
| 2 | $0.79 | 40,000 | $32K | 28.3% |
| Total | $0.80 avg | 140,000 | $112K | 100% |
| Filing → |
| AYTU | BUY | 2020-12-15 | $8.0M | — | Filing → |
| CERC | BUY | 2020-12-07 | $49K | — | Filing → |
| RSLS | BUY | 2020-11-12 | $9K | — | Filing → |